This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Early Winners & Losers

Novastar Financial (NFI) plummeted some 28% in after-hours action Tuesday as the nonprime lender posted dismal fourth-quarter results. The Missouri-based company lost $11.9 million from continuing operations, or 32 cents a share, compared with last year's profit of $28.5 million, or 73 cents a share. Analysts polled by Thomson Financial were looking for flat year-over-year income.

The Missouri-based company also announced it may shed its status as a real estate investment trust post-2007, given that it is compelled as a REIT to pay out 90% of taxable income via dividends, and expects to see "little, if any, taxable income" from 2007 through 2011. Shares were losing $4.88 to $12.68.

Semiconductor Pixelworks (PXLW - Get Report) announced Samsung Electronics will use its "Bluejay" chip, which eliminates video distortion, in two of its slim, traditional-model television designs. Shares of the Tualatin, Ore.-based company were gaining 22 cents, or 10.8%, to $2.25.

AmSurg (AMSG - Get Report) climbed after the Nashville-based operator of ambulatory surgery centers reported fourth-quarter income from continuing operations of $10 million, or 33 cents a share, up from $8.4 million, or 28 cents a share, a year ago. Revenue rose 17% to $118.9 million. The Street was looking for 32 cents a share on $116.5 million revenue. The company also expects 2007 sales of $510 million to $530 million -- at least $46.4 million above estimates. Shares were up $1.71, or 7.5%, to $24.65.

Nanogen (NGEN), based in San Diego, narrowed its fourth-quarter loss to $11.2 million, or 17 cents a share, from $69.7 million, or $1.27 million a year ago. The diagnostic-products maker's sales soared to $8.7 million from $3.1 million last year. Shares were adding 7 cents, or 4.8%, to $1.52.

Dyax (DYAX) was plunging after the Cambridge, Mass., biotech and Genzyme (GENZ) ended their nine-year joint venture to develop a treatment called DX-88 for hereditary angioedema, a rare blood disease. Dyax will retain all rights to the drug and $17 million besides, while Genzyme will receive 4.4 million Dyax shares. Dyax will continue to develop the drug and says this decision won't skew anything in the way of that. Dyax shares were declining 68 cents, or 15.7%, to $3.65. Genzyme's shares were unchanged after closing the regular session at $65.75, up 55 cents.

Hawaiian Airlines' parent company, Hawaiian Holdings (HA - Get Report), was lower on fourth-quarter operating losses that widened to $13.9 million from $10.3 million last year. Overall losses narrowed to $9.6 million, or 20 cents a share, from last year's $19.5 million, or 43 cents a share; also, sales edged up 3.6% to $219.6 million. But revenue per passenger was down 1.8% to 10.83 cents, and load factor (a measure of passenger traffic) was down 4.5 points to 85.2%. Shares were losing 28 cents, or 4.4%, to $6.05.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NGEN $0.00 100.00%
DYAX $38.41 0.00%
AMSG $75.53 -6.60%
HA $41.01 -3.30%
PXLW $2.00 -0.50%


Chart of I:DJI
DOW 17,619.52 -131.39 -0.74%
S&P 500 2,048.72 -14.65 -0.71%
NASDAQ 4,722.1060 -41.1180 -0.86%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs